Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial).

Trial Profile

Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2015

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms RATE
  • Most Recent Events

    • 19 Dec 2011 Planned End Date changed from 30 Nov 2013 to 31 Aug 2014 as reported by Netherlands Trial Register record.
    • 19 Dec 2011 Additional trial centre and investigator identified as reported by Netherlands Trial Register record.
    • 18 Dec 2011 New source identified and integrated (Netherlands Trial Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top